SMAD4 and nasopharyngeal carcinoma: In a GWAS, a 24.3% (17/70 tumors) rate of TGF-β/SMAD pathway gene alteration was observed in NPC, targeting TGFBR2, TGFBR3, ACVR2A, and SMAD4 [74].